Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany

BACKGROUND: Erenumab, the first-in-class fully human monoclonal antibody targeting the calcitonin gene-related peptide receptor, was shown to be efficacious and safe for the prophylactic treatment of migraine in adults in randomized clinical trials. Large-scale, real-world evidence in multi-centre s...

Descripción completa

Detalles Bibliográficos
Autores principales: Straube, Andreas, Stude, Philipp, Gaul, Charly, Schuh, Katrin, Koch, Mirja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572451/
https://www.ncbi.nlm.nih.gov/pubmed/34742252
http://dx.doi.org/10.1186/s10194-021-01344-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572451/
https://www.ncbi.nlm.nih.gov/pubmed/34742252
http://dx.doi.org/10.1186/s10194-021-01344-1

Ejemplares similares